» Articles » PMID: 32513900

Unlabeled Lysophosphatidic Acid Receptor Binding in Free Solution As Determined by a Compensated Interferometric Reader

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2020 Jun 10
PMID 32513900
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Native interactions between lysophospholipids (LPs) and their cognate LP receptors are difficult to measure because of lipophilicity and/or the adhesive properties of lipids, which contribute to high levels of nonspecific binding in cell membrane preparations. Here, we report development of a free-solution assay (FSA) where label-free LPs bind to their cognate G protein-coupled receptors (GPCRs), combined with a recently reported compensated interferometric reader (CIR) to quantify native binding interactions between receptors and ligands. As a test case, the binding parameters between lysophosphatidic acid (LPA) receptor 1 (LPA; one of six cognate LPA GPCRs) and LPA were determined. FSA-CIR detected specific binding through the simultaneous real-time comparison of bound versus unbound species by measuring the change in the solution dipole moment produced by binding-induced conformational and/or hydration changes. FSA-CIR identified values for chemically distinct LPA species binding to human LPA and required only a few nanograms of protein: 1-oleoyl (18:1; = 2.08 ± 1.32 nM), 1-linoleoyl (18:2; = 2.83 ± 1.64 nM), 1-arachidonoyl (20:4; = 2.59 ± 0.481 nM), and 1-palmitoyl (16:0; = 1.69 ± 0.1 nM) LPA. These values compared favorably to those obtained using the previous generation back-scattering interferometry system, a chip-based technique with low-throughput and temperature sensitivity. In conclusion, FSA-CIR offers a new increased-throughput approach to assess quantitatively label-free lipid ligand-receptor binding, including nonactivating antagonist binding, under near-native conditions.

Citing Articles

Electric field-enhanced backscatter interferometry detection for capillary electrophoresis.

De Silva M, Dunn R Sci Rep. 2024; 14(1):2110.

PMID: 38267528 PMC: 10808210. DOI: 10.1038/s41598-024-52621-3.


FTY720 requires vitamin B-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis.

Jonnalagadda D, Kihara Y, Groves A, Ray M, Saha A, Ellington C Cell Rep. 2023; 42(12):113545.

PMID: 38064339 PMC: 11066976. DOI: 10.1016/j.celrep.2023.113545.


Entering, Linked with the Sphinx: Lysophosphatidic Acids Everywhere, All at Once, in the Oral System and Cancer.

Cerutis D, Weston M, Miyamoto T Int J Mol Sci. 2023; 24(12).

PMID: 37373424 PMC: 10299546. DOI: 10.3390/ijms241210278.


Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA), UCM-14216, Ameliorates Spinal Cord Injury in Mice.

Khiar-Fernandez N, Zian D, Vazquez-Villa H, Martinez R, Escobar-Pena A, Foronda-Sainz R J Med Chem. 2022; 65(16):10956-10974.

PMID: 35948083 PMC: 9421655. DOI: 10.1021/acs.jmedchem.2c00046.


Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P -selective modulation.

Kihara Y, Jonnalagadda D, Zhu Y, Ray M, Ngo T, Palmer C FASEB J. 2022; 36(2):e22132.

PMID: 34986275 PMC: 8740777. DOI: 10.1096/fj.202101531R.


References
1.
Lummis N, Sanchez-Pavon P, Kennedy G, Frantz A, Kihara Y, Blaho V . LPA overactivation induces neonatal posthemorrhagic hydrocephalus through ependymal loss and ciliary dysfunction. Sci Adv. 2019; 5(10):eaax2011. PMC: 6785248. DOI: 10.1126/sciadv.aax2011. View

2.
Cohen J, Chun J . Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011; 69(5):759-77. DOI: 10.1002/ana.22426. View

3.
Locatelli-Hoops S, Yeliseev A, Gawrisch K, Gorshkova I . Surface plasmon resonance applied to G protein-coupled receptors. Biomed Spectrosc Imaging. 2014; 2(3):155-181. PMC: 3898597. DOI: 10.3233/BSI-130045. View

4.
Chun J, Kihara Y, Jonnalagadda D, Blaho V . Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. Annu Rev Pharmacol Toxicol. 2019; 59:149-170. PMC: 6392001. DOI: 10.1146/annurev-pharmtox-010818-021358. View

5.
Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K . Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999; 274(39):27776-85. DOI: 10.1074/jbc.274.39.27776. View